Biased Allostery

Biophysical Journal

Volumn 111, Issue 5, 2016, Pages 902-908

  Edelstein, Stuart J ^a   Changeux, Jean Pierre ^b,c  

^a PSL RESEARCH UNIVERSITY   (France)

^b l'alimentation et l'Environnement   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; PROTEIN BINDING;

AGONISTS; ALLOSTERISM; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; METABOLISM; MOLECULAR MODEL;

ALLOSTERIC REGULATION; ANIMALS; MODELS, MOLECULAR; PROTEIN BINDING; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84995686992     PISSN: 00063495     EISSN: 15420086     Source Type: Journal    
DOI: 10.1016/j.bpj.2016.07.044     Document Type: Review

References (64)

1. 1 Galandrin, S., Oligny-Longpré, G., Bouvier, M., The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol. Sci. 28 (2007), 423–430.
2. 2 Reiter, E., Ahn, S., et al., Lefkowitz, R.J., Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. Annu. Rev. Pharmacol. Toxicol. 52 (2012), 179–197.
3. 3 Kenakin, T., Christopoulos, A., Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat. Rev. Drug Discov. 12 (2013), 205–216.
4. 4 Lefkowitz, R.J., G protein-coupled receptors. III. New roles for receptor kinases and β-arrestins in receptor signaling and desensitization. J. Biol. Chem. 273 (1998), 18677–18680.
5. 5 Kahsai, A.W., Xiao, K., et al., Lefkowitz, R.J., Multiple ligand-specific conformations of the β2-adrenergic receptor. Nat. Chem. Biol. 7 (2011), 692–700.
6. 6 Manglik, A., Kim, T.H., et al., Kobilka, B.K., Structural insights into the dynamic process of β2-adrenergic receptor signaling. Cell 161 (2015), 1101–1111.
7. 7 Monod, J., Wyman, J., Changeux, J.-P., On the nature of allosteric transitions: a plausible model. J. Mol. Biol. 12 (1965), 88–118.
8. 8 Leff, P., Scaramellini, C., et al., McKechnie, K., A three-state receptor model of agonist action. Trends Pharmacol. Sci. 18 (1997), 355–362.
9. 9 Christopoulos, A., Kenakin, T., G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54 (2002), 323–374.
10. 10 Canals, M., Lane, J.R., et al., Christopoulos, A., A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation. J. Biol. Chem. 287 (2012), 650–659.
11. 11 Roth, S., Bruggeman, F.J., A conformation-equilibrium model captures ligand-ligand interactions and ligand-biased signalling by G-protein coupled receptors. FEBS J. 281 (2014), 4659–4671.
12. 12 Changeux, J.P., Edelstein, S.J., Allosteric mechanisms of signal transduction. Science 308 (2005), 1424–1428.
13. 13 Cui, Q., Karplus, M., Allostery and cooperativity revisited. Protein Sci. 17 (2008), 1295–1307.
14. 14 Changeux, J.P., Edelstein, S., Conformational selection or induced fit? 50 years of debate resolved. F1000 Biol. Rep., 3, 2011, 19.
15. 15 Motlagh, H.N., Wrabl, J.O., et al., Hilser, V.J., The ensemble nature of allostery. Nature 508 (2014), 331–339.
16. 16 Dror, R.O., Arlow, D.H., et al., Shaw, D.E., Activation mechanism of the β2-adrenergic receptor. Proc. Natl. Acad. Sci. USA 108 (2011), 18684–18689.
17. 17 Boehr, D.D., Nussinov, R., Wright, P.E., The role of dynamic conformational ensembles in biomolecular recognition. Nat. Chem. Biol. 5 (2009), 789–796.
18. 18 Nussinov, R., Tsai, C.J., Allostery without a conformational change? Revisiting the paradigm. Curr. Opin. Struct. Biol. 30 (2015), 17–24.
19. 19 Tzeng, S.R., Kalodimos, C.G., Protein activity regulation by conformational entropy. Nature 488 (2012), 236–240.
20. 20 Vischer, H.F., Castro, M., Pin, J.P., G protein-coupled receptor multimers: a question still open despite the use of novel approaches. Mol. Pharmacol. 88 (2015), 561–571.
21. 21 Ferré, S., The GPCR heterotetramer: challenging classical pharmacology. Trends Pharmacol. Sci. 36 (2015), 145–152.
22. 22 Endres, N.F., Barros, T., et al., Kuriyan, J., Emerging concepts in the regulation of the EGF receptor and other receptor tyrosine kinases. Trends Biochem. Sci. 39 (2014), 437–446.
23. 23 Rubin, M.M., Changeux, J.-P., On the nature of allosteric transitions: implications of non-exclusive ligand binding. J. Mol. Biol. 21 (1966), 265–274.
24. 24 Duhr, F., Déléris, P., et al., Chaumont-Dubel, S., Cdk5 induces constitutive activation of 5-HT6 receptors to promote neurite growth. Nat. Chem. Biol. 10 (2014), 590–597.
25. 25 Azzi, M., Charest, P.G., et al., Piñeyro, G., β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc. Natl. Acad. Sci. USA 100 (2003), 11406–11411.
26. 26 Kenakin, T., What is pharmacological “affinity”? Relevance to biased agonism and antagonism. Trends Pharmacol. Sci. 35 (2014), 434–441.
27. 27 Galzi, J.L., Edelstein, S.J., Changeux, J., The multiple phenotypes of allosteric receptor mutants. Proc. Natl. Acad. Sci. USA 93 (1996), 1853–1858.
28. 28 Gregory, K.J., Hall, N.E., et al., Christopoulos, A., Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. J. Biol. Chem. 285 (2010), 7459–7474.
29. 29 Valentin-Hansen, L., Frimurer, T.M., et al., Schwartz, T.W., Biased Gs versus Gq proteins and β-arrestin signaling in the NK1 receptor determined by interactions in the water hydrogen bond network. J. Biol. Chem. 290 (2015), 24495–24508.
30. 30 Sbai, O., Monnier, C., et al., Rondard, P., Biased signaling through G-protein-coupled PROKR2 receptors harboring missense mutations. FASEB J. 28 (2014), 3734–3744.
31. 31 Zhang, Y., Rodriguez, A.L., Conn, P.J., Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J. Pharmacol. Exp. Ther. 315 (2005), 1212–1219.
32. 32 Eriksson, M., Uhlin, U., et al., Eklund, H., Binding of allosteric effectors to ribonucleotide reductase protein R1: reduction of active-site cysteines promotes substrate binding. Structure 5 (1997), 1077–1092.
33. 33 Thal, D.M., Sun, B., et al., Christopoulos, A., Crystal structures of the M1 and M4 muscarinic acetylcholine receptors. Nature 531 (2016), 335–340.
34. 34 Manglik, A., Kobilka, B., The role of protein dynamics in GPCR function: insights from the β2AR and rhodopsin. Curr. Opin. Cell Biol. 27 (2014), 136–143.
35. 35 Shukla, A.K., Singh, G., Ghosh, E., Emerging structural insights into biased GPCR signaling. Trends Biochem. Sci. 39 (2014), 594–602.
36. 36 Shukla, A.K., Westfield, G.H., et al., Lefkowitz, R.J., Visualization of arrestin recruitment by a G-protein-coupled receptor. Nature 512 (2014), 218–222.
37. 37 Kang, Y., Zhou, X.E., et al., Xu, H.E., Crystal structure of rhodopsin bound to arrestin by femtosecond x-ray laser. Nature 523 (2015), 561–567.
38. 38 Liu, J.J., Horst, R., et al., Wüthrich, K., Biased signaling pathways in β2-adrenergic receptor characterized by 19F-NMR. Science 335 (2012), 1106–1110.
39. 39 Kruse, A.C., Ring, A.M., et al., Kobilka, B.K., Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504 (2013), 101–106.
40. 40 Dror, R.O., Mildorf, T.J., et al., Shaw, D.E., SIGNAL TRANSDUCTION. Structural basis for nucleotide exchange in heterotrimeric G proteins. Science 348 (2015), 1361–1365.
41. 41 Black, J.W., Leff, P., Operational models of pharmacological agonism. Proc. R. Soc. Lond. B Biol. Sci. 220 (1983), 141–162.
42. 42 Black, J.W., Leff, P., et al., Wood, J., An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation. Br. J. Pharmacol. 84 (1985), 561–571.
43. 43 Kenakin, T., Watson, C., et al., Novick, S., A simple method for quantifying functional selectivity and agonist bias. ACS Chem. Neurosci. 3 (2012), 193–203.
44. 44 Edelstein, S.J., Schaad, O., et al., Changeux, J.P., A kinetic mechanism for nicotinic acetylcholine receptors based on multiple allosteric transitions. Biol. Cybern. 75 (1996), 361–379.
45. 45 Edelstein, S.J., Stefan, M.I., Le Novère, N., Ligand depletion in vivo modulates the dynamic range and cooperativity of signal transduction. PLoS One, 5, 2010, e8449.
46. 46 Edelstein, S.J., A novel equation for cooperativity of the allosteric state function. J. Mol. Biol. 426 (2014), 39–42.
47. 47 Casella, I., Ambrosio, C., et al., Costa, T., Divergent agonist selectivity in activating β1- and β2-adrenoceptors for G-protein and arrestin coupling. Biochem. J. 438 (2011), 191–202.
48. 48 Pin, J.P., Neubig, R., et al., Spedding, M., International union of basic and clinical pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol. Rev. 59 (2007), 5–13.
49. 49 Gherbi, K., May, L.T., et al., Hill, S.J., Negative cooperativity across β1-adrenoceptor homodimers provides insights into the nature of the secondary low-affinity CGP 12177 β1-adrenoceptor binding conformation. FASEB J. 29 (2015), 2859–2871.
50. 50 Palanche, T., Ilien, B., et al., Galzi, J.L., The neurokinin A receptor activates calcium and cAMP responses through distinct conformational states. J. Biol. Chem. 276 (2001), 34853–34861.
51. 51 Klein Herenbrink, C., Sykes, D.A., et al., Lane, J.R., The role of kinetic context in apparent biased agonism at GPCRs. Nat. Commun., 7, 2016, 10842.
52. 52 Sounier, R., Mas, C., et al., Granier, S., Propagation of conformational changes during μ-opioid receptor activation. Nature 524 (2015), 375–378.
53. 53 Nygaard, R., Zou, Y., et al., Kobilka, B.K., The dynamic process of β(2)-adrenergic receptor activation. Cell 152 (2013), 532–542.
54. 54 Lee, Y., Choi, S., Hyeon, C., Communication over the network of binary switches regulates the activation of A2A adenosine receptor. PLOS Comput. Biol., 11, 2015, e1004044.
55. 55 Bovet, D., The relationships between isosterism and competitive phenomena in the field of drug therapy of the autonomic nervous system and that of the neuromuscular transmission. Physiology or Medicine: 1963–1970 (Nobel lectures), 1957, Elsevier, Amsterdam, the Netherlands.
56. 56 Lamichhane, R., Liu, J.J., et al., Millar, D.P., Single-molecule view of basal activity and activation mechanisms of the G protein-coupled receptor β2AR. Proc. Natl. Acad. Sci. USA 112 (2015), 14254–14259.
57. 57 Vafabakhsh, R., Levitz, J., Isacoff, E.Y., Conformational dynamics of a class C G-protein-coupled receptor. Nature 524 (2015), 497–501.
58. 58 Edelstein, S.J., Schaad, O., Changeux, J.-P., Single binding versus single channel recordings: a new approach to study ionotropic receptors. Biochemistry 36 (1997), 13755–13760.
59. 59 Rasmussen, S.G., DeVree, B.T., et al., Kobilka, B.K., Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 477 (2011), 549–555.
60. 60 Doumazane, E., Scholler, P., et al., Rondard, P., Illuminating the activation mechanisms and allosteric properties of metabotropic glutamate receptors. Proc. Natl. Acad. Sci. USA 110 (2013), E1416–E1425.
61. 61 DeVree, B.T., Mahoney, J.P., et al., Sunahara, R.K., Allosteric coupling from G protein to the agonist-binding pocket in GPCRs. Nature 535 (2016), 182–186.
62. 62 Gurevich, V.V., Pals-Rylaarsdam, R., et al., Onorato, J.J., Agonist-receptor-arrestin, an alternative ternary complex with high agonist affinity. J. Biol. Chem. 272 (1997), 28849–28852.
63. 63 Changeux, J.P., 50 years of allosteric interactions: the twists and turns of the models. Nat. Rev. Mol. Cell Biol. 14 (2013), 819–829.
64. 64 Roth, B.L., DREADDs for neuroscientists. Neuron 89 (2016), 683–694.